The deeper threat to the biopharmaceutical industry may come not from macro-level disruption, but from structural pressures ...

Eli Lilly and Company has broken ground on a new $5-billion manufacturing facility in Goochland County, Virginia, west of Richmond, Virginia, which will produce active pharmaceutical ingredients (APIs ...

Sun Pharma’s pending $11.75-billion acquisition of Organon was one of the largest M&A in 2026 and is aligned with its strategy of in part diversifying into innovator drugs, a step taken by other ...

How AI and other digital tools are progressing across the bio/pharmaceutical industry is on top of mind. Key perspectives on ...

In what is projected to be one of the largest IPOs in history, the AI giant, Anthropic, has taken the first step in holding an IPO, with AI in bio/pharmaceutical development a key component in its ...

Merck KGaA has agreed to acquire Silence Therapeutics, a Cambridge, UK-based clinical-stage bio/pharmaceutical company developing short interfering RNA (siRNA) medicines, for $1.3 billion, ...

Sanofi has broken ground on a new insulin manufacturing facility in Frankfurt, Germany. The new facility will be built on a 36,000-square-meter footprint at the Sanofi BioCampus in Frankfurt.

The Board of Directors of CSL, a Melbourne, Australia-based bio/pharmaceutical company, has appointed Deborah Waterhouse, currently Chief Executive Officer (CEO) of ViiV Healthcare, a joint venture ...

BD (Becton, Dickinson and Company), a medical technology company, has announced a partnership with the US government under which the company has agreed to invest $19 billion in the US over several ...

An important recent trend in parenteral drugs is the development of subcutaneous (i.e., under the skin) delivery through injectables for bio/pharmaceuticals that were administered intravenously (IV).